Berkshire Hathaway Vice-Chairman Charlie Munger had some harsh words to say about Valeant Pharmaceuticals. » Read More
Drugmaker Roche on Thursday reported full-year earnings and a dividend slightly below forecasts and said it expected sales to grow low- to mid-single digit in 2016.
The "Fast Money" traders give their final trades of the day.
Massachusetts AG Maura Healey said the costs of two drugs "may constitute an unfair trade practice in violation of Massachusetts law."
Scientists developed a device to prevent implanted insulin-producing cells from being attacked by the immune system for six months.
CNBC's Meg Tirrell breaks down the quarterly numbers on Biogen and Novartis.
Biogen's quarterly profit breezed past Wall Street's estimates, driven by higher demand for its key oral multiple sclerosis drug Tecfidera.
Cathrin Petty, head of EMEA healthcare at JP Morgan, says 2016 will be a pivotal year for the health care industry due to new product launches and approvals, as well as commercial headwinds.
CNBC correspondent Julia Chatterley reports on Novartis' 4th quarter net income of $2.7 billion, which was below forecasts.
Xavier Rolet, CEO of the London Stock Exchange, talks about the success pharma and health care companies have had raising capital in the U.K.
CNBC's Meg Tirrell highlights the increasingly popular political stance against increasing drug prices.
Donald Trump reportedly supports Medicare negotiating the price of prescription drugs, claiming it would save $300 billion annually.
CNBC takes a look at Zika, a mosquito-borne virus spreading fast across the Americas and the Caribbean for which there is no cure.
The Nasdaq biotech index traded lower following a tweet from Hillary Clinton disparaging higher drug prices, reports CNBC's Meg Tirrell.
Former Medtronic CEO Bill George matches up industry competitors and offers up this scorecard of CEOs with solid strategies that are worth betting on.
Valeant's ailing CEO, Michael Pearson, said he was on the road to recovery but was uncertain about when he would return from medical leave.
Cigna said the suspension does not affect members currently enrolled in these plans.
Valeant's interim chairman and CEO say the pharma giant is making changes in "a number of areas" to "correct our missteps."
The controversial former drug exec, facing fraud charges, is also objecting to being a called a "pharma bro."
Peder Holk Nielsen, CEO of Novozymes, explains why the company has downgraded its outlook for sales growth.
Health care CEOs discuss the three traits they believe define what makes a good leader.
Get the best of CNBC in your inbox